A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives.
Epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) disease biology may differ from EGFR-wild type NSCLC, with an increased risk of distant metastases in unresectable stage III EGFRm NSCLC. Osimertinib is an established first treatment for patients with EGFRm advanced NSCLC, effectively...